Protagonist CEO sells 125K shares after option exercise

PTGX’s CEO exercised 125,000 options and sold the resulting shares over three days under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. (PTGX) reported that President and CEO Dinesh V. Patel exercised fully vested stock options for 125,000 shares of common stock at an exercise price of $21.58 per share on September 8, 9 and 10, 2026, and sold the same 125,000 shares in market or private transactions on those dates. The reported sale prices were weighted average prices of $145.87, $146.18 and $144.10 per share, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on January 30, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 125,000 shares ($15.54M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider PATEL DINESH V PH D

Role President and CEO

Sold 125,000 shs ($18.24M)

Approx. gross sale proceeds $18.24M

Approx. exercise cost $2.70M

Approx. pre-tax spread $15.54M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1	7,278	$0.00	$0.00
Exercise	Common Stock F1	7,278	$21.58	$157K
Sale	Common Stock F4	7,278	$144.10	$1.05M
Exercise	Stock Option (right to buy) F1	63,548	$0.00	$0.00
Exercise	Common Stock F1	63,548	$21.58	$1.37M
Sale	Common Stock F3	63,548	$146.18	$9.29M
Exercise	Stock Option (right to buy) F1	54,174	$0.00	$0.00
Exercise	Common Stock F1	54,174	$21.58	$1.17M
Sale	Common Stock F2	54,174	$145.87	$7.90M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 522,968 shares (Direct)

Footnotes (4)

1. F1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
4. F4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Total shares exercised: 125,000 shares Total shares sold: 125,000 shares Option exercise price: $21.58 per share +5 more

8 metrics

Total shares exercised 125,000 shares Stock options exercised into common stock on September 8–10, 2026

Total shares sold 125,000 shares Common shares sold in market or private transactions on September 8–10, 2026

Option exercise price $21.58 per share Exercise price of stock options converted into common stock

Weighted average sale price September 8, 2026 $145.87 per share Shares sold in multiple transactions within a price range

Weighted average sale price September 9, 2026 $146.18 per share Shares sold in multiple transactions within a price range

Weighted average sale price September 10, 2026 $144.10 per share Shares sold in multiple transactions within a price range

Rule 10b5-1 plan adoption date January 30, 2026 Date the pre-arranged trading plan governing these transactions was adopted

Option expiration date October 11, 2026 Expiration date of the fully vested stock options exercised

Key Terms

Rule 10b5-1 plan, weighted average sale price per share, fully vested stock options, common stock

4 terms

Rule 10b5-1 plan regulatory

"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price per share financial

"The price reported represents the weighted average sale price per share."

fully vested stock options financial

"The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."

common stock financial

"and the sale of shares of common stock acquired upon exercise of the stock options."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What insider transactions did PTGX’s CEO report in this Form 4?

President and CEO Dinesh V. Patel reported exercising stock options for 125,000 shares of Protagonist Therapeutics common stock and selling the same 125,000 shares in transactions dated September 8, 9 and 10, 2026.

At what prices did the PTGX CEO sell shares reported in this filing?

The reported weighted average sale prices were $145.87 per share on September 8, 2026, $146.18 per share on September 9, 2026, and $144.10 per share on September 10, 2026, with each day’s sales executed in multiple price ranges disclosed in the footnotes.

What was the stock option exercise price in the PTGX CEO’s Form 4?

The stock options exercised by the PTGX CEO carried an exercise price of $21.58 per share. On each of September 8, 9 and 10, 2026, options were exercised at this price and converted into common shares that were then sold the same day.

How many PTGX shares did the CEO exercise and sell on each date?

On September 8, 2026, 54,174 shares were exercised and sold; on September 9, 2026, 63,548 shares were exercised and sold; and on September 10, 2026, 7,278 shares were exercised and sold, for a total of 125,000 shares across the three days.

Were the PTGX CEO’s transactions made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on January 30, 2026. The plan provides for exercising fully vested options expiring October 11, 2026 and selling the shares acquired upon exercise.

What type of securities did the PTGX CEO exercise in this filing?

The PTGX CEO exercised stock options that were fully vested and scheduled to expire on October 11, 2026. Each option entitled the holder to purchase one share of Protagonist Therapeutics common stock at an exercise price of $21.58 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 09:18 PM Accepted by SEC EDGAR 09/10/2026 - 09:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		M(1)		54,174	A	$21.58	577,142	D
Common Stock	09/08/2026		S		54,174	D	$145.87(2)	522,968	D
Common Stock	09/09/2026		M(1)		63,548	A	$21.58	586,516	D
Common Stock	09/09/2026		S		63,548	D	$146.18(3)	522,968	D
Common Stock	09/10/2026		M(1)		7,278	A	$21.58	530,246	D
Common Stock	09/10/2026		S		7,278	D	$144.1(4)	522,968	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.58	09/08/2026		M			54,174	(1)	10/11/2026	Common Stock	54,174	$0.00	70,826	D
Stock Option (right to buy)	$21.58	09/09/2026		M			63,548	(1)	10/11/2026	Common Stock	63,548	$0.00	7,278	D
Stock Option (right to buy)	$21.58	09/10/2026		M			7,278	(1)	10/11/2026	Common Stock	7,278	$0.00	0	D

Explanation of Responses:

1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)